50 reports

  • lists drugs in early-stage development for ovarian cancer that GlobalData identified for their novel approaches.
  • COMMERCIAL BENCHMARK OF KEY PIPELINE IMMUNO-ONCOLOGY DRUGS - OVARIAN CANCER

Dostarlimab is a humanized monoclonal antibody targeting PD-##, similar to blockbuster drugs Keytruda and Opdivo.

  • Ovarian Cancer
  • United States
  • Forecast
  • AstraZeneca PLC
  • Roche Group

These companies will evaluate the efficacy and safety of epacadostat, investigational selective IDO## enzymes inhibitor in combination with AstraZeneca' s Imfinzi, a human monoclonal antibody directed against PD-L## comapred to Imfinzi alone.

  • Ovarian Cancer
  • World
  • AbbVie Inc.
  • AstraZeneca PLC
  • Clovis Oncology, Inc.

The project of I## labeled hepatocarcinoma monoclonal antibody injection, cooperated with the Fourth Military Medical University, has now completed clinical phase study.

  • Ovarian Cancer
  • China
  • Demand
  • Bayer Schering Pharmaceutical Co., Ltd
  • Roche Group

Monoclonal antibodies such as mepolizumab and omalizumab are sometimes effective.

  • Cough And Cold
  • China
  • Demand
  • Market Size
  • Trade

The project of I## labeled hepatocarcinoma monoclonal antibody injection, cooperated with the Fourth Military Medical University, has now completed clinical phase study.

  • Ovarian Cancer
  • China
  • Demand
  • Bayer Schering Pharmaceutical Co., Ltd
  • Roche Group

Monoclonal antibodies such as mepolizumab and omalizumab are sometimes effective.

  • Cough And Cold
  • China
  • Demand
  • Market Size
  • GlaxoSmithKline plc

KOL PERSPECTIVE ON THE USE OF PARP INHIBITORS VERSUS BEVACIZUMAB, AN ANGIOGENESIS INHIBITOR MONOCLONAL ANTIBODY TARGETING VEGF-A KOL PERSPECTIVE What are the factors that lead to use of PARP inhibitors versus bevacizumab?

  • Ovarian Cancer
  • Targeted Therapy
  • United States
  • AbbVie Inc.
  • Pfizer Inc.
  • MONOCLONAL ANTIBODY TO INHIBIT CD73 FOR NON SMALL CELL LUNG CANCER AND OVARIAN CANCER - DRUG PROFILE
  • BISPECIFIC MONOCLONAL ANTIBODY TO INHIBIT CD73 FOR NON-SMALL CELL LUNG CANCER AND OVARIAN CANCER - DRUG PROFILE

Monoclonal antibody acts by inhibiting CD##.

  • Medical Biotechnology
  • Ovarian Cancer
  • United States
  • Company Operations
  • Product Initiative

Pasteur Institute NA NA MONOCLONAL ANTIBODY TO ANTAGONIZE FCGRIIA FOR AUTOIMMUNE ARTHRITIS, PULMONARY INFLAMMATION, SYSTEMIC ANAPHYLAXIS AND THROMBOCYTOPENIA - DRUG PROFILE Drug Name Company/ Institute Name Licensed From Company Development Partner Product Description

  • Cough And Cold
  • Therapy
  • United States
  • World
  • Product Initiative
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H1 2018 (CONTD..1), H1 2018

DPX-Survivac collaborates with Peregrine aims to determine the potential synergistic effects of combining DPX-Survivac with bavituximab, Peregrine s investigational chimeric monoclonal antibody that targets phosphatidylserine (PS. )

  • Immunotherapy
  • Ovarian Cancer
  • United States
  • World
  • Product Initiative

It also develops a product CORVUS PHARMACEUTICALS INC ARRIEN PHARMACEUTICALS LLC Pipeline by Corvus Pharmaceuticals Inc, H## 2018 candidate, an anti-CD## monoclonal antibody that inhibits the production of adenosine produced by the tumor cells.

  • Immunotherapy
  • Ovarian Cancer
  • Renal Cancer
  • Therapy
  • Novartis AG

For the same PAMAM dendrimers have been boronated to act as monoclonal antibody immunoconjugates to ensure targeted drug delivery.

  • Ovarian Cancer
  • United States
  • Demand
  • Forecast
  • Nektar Therapeutics
  • FEATURED NEWS & PRESS RELEASES

Its preclinical programs comprise a PD-L## monoclonal antibody, an additional RAF dimer inhibitor, a TIM-## cell surface protein monoclonal antibody, and a BTK inhibitor for non-oncology indications.

  • Oncology
  • Ovarian Cancer
  • Targeted Therapy
  • Therapy
  • AstraZeneca PLC

Research on SurVaxM has led to the development of additional platform agents, including a therapeutic anti-survivin monoclonal antibody and survivin-targeted CAR T cells, both of which are under development by scientists and clinicians at MimiVax and Roswell Park.

  • Immunotherapy
  • Ovarian Cancer
  • Pharmaceutical
  • Therapy
  • Immunovaccine Inc.

Most recently she served as the Worldwide Brand Director at Novartis Pharmaceuticals Corporation, where she was the global launch lead for Aimovig®, the first monoclonal antibody approved by the U. S.

  • Cough And Cold
  • HIV AIDS
  • Ovarian Cancer
  • United States
  • AcelRx Pharmaceuticals, Inc.

The drug candidate is a combination of multi-kinase angiogenesis inhibitor and PD-## monoclonal antibody.

  • Immunotherapy
  • Ovarian Cancer
  • Renal Cancer
  • Therapy
  • Novartis AG

The drug candidate is a monoclonal antibody that inhibits binding of IL-## to the ST## receptor.

  • Cough And Cold
  • Pharmaceutical
  • Therapy
  • United States
  • Product Initiative
  • APR 02, 2018: MYRIAD RECEIVES PRE-MARKET APPROVAL FOR ITS BRACANALYSIS DIAGNOSTIC SYSTEM IN JAPAN

Its preclinical programs comprise a PD-L## monoclonal antibody, an additional RAF dimer inhibitor, a TIM-## cell surface protein monoclonal antibody, and a BTK inhibitor for non-oncology indications.

  • Oncology
  • Ovarian Cancer
  • Therapy
  • United States
  • AstraZeneca PLC
  • PIPELINE BY MEDIMMUNE, LLC, H2 2016
  • DORMANT PROJECTS (CONTD..1), H2 2016

It is a bi-specific monoclonal antibody comprised of two different heavy chains and two different light chains.

  • Ovarian Cancer
  • United States
  • World
  • Product Initiative
  • Amgen Inc.
  • May 03, 2018: TESARO Announces First-Quarter 2018 Operating Results

TSR-## (anti-PD-## antibody) TSR-## is a monoclonal antibody targeting PD-## and was developed as part of the collaboration between TESARO and AnaptysBio, Inc.

  • Chemotherapy
  • Healthcare
  • Ovarian Cancer
  • Pharmaceutical
  • Targeted Therapy
  • May 03, 2018: TESARO Announces First-Quarter 2018 Operating Results

About VARUBI®(rolapitant) TSR-## is a monoclonal antibody targeting PD-## and was developed as part of the collaboration between TESARO and AnaptysBio, Inc.

  • Ovarian Cancer
  • United States
  • Company
  • Company Financials
  • TESARO, Inc.
  • Official Title
  • Official Title

Open-Label, Phase IIa Study with the Intraperitoneally Infused Trifunctional Bispecific Antibody Removab (Anti-EpCAM x Anti-CD##) to Select the Better Dose Level in Platinum Refractory Epithelial Ovarian Cancer Patients Randomized, Multicenter, ##-Dose Level.

  • Drug Development
  • Ovarian Cancer
  • Pharmaceutical
  • World
  • Product Initiative

It also develops a product candidate, an anti-CD## monoclonal antibody that inhibits the production of adenosine produced by the tumor cells.

  • Cough And Cold
  • Pharmaceutical
  • Therapy
  • United States
  • Vernalis plc
  • Clinical Trial profile. 153 Trial Title

## ## ## Merck & Co Inc ## ## ## ## ## ## AstraZeneca Plc ## ## ## ## ## ## Eli Lilly and Co ## ## ## ## ## ## GlaxoSmithKline Plc ## ## ## ## ## ## Novartis AG ## ## ## ## ## ## Pfizer Inc ## ## ## ## ## ## Italian Sarcoma Group ## ## ##

  • Drug Development
  • Medical Biotechnology
  • Ovarian Cancer
  • World
  • Product Initiative
  • APR 02, 2018: MYRIAD RECEIVES PRE-MARKET APPROVAL FOR ITS BRACANALYSIS DIAGNOSTIC SYSTEM IN JAPAN

Its preclinical programs comprise a PD-L## monoclonal antibody, an additional RAF dimer inhibitor, a TIM-## cell surface protein monoclonal antibody, and a BTK inhibitor for non-oncology indications.

  • Cancer
  • Ovarian Cancer
  • United States
  • Product Initiative
  • AstraZeneca PLC
  • DIAGNOSTIC ASSAY - OVARIAN CANCER - PRODUCT DESCRIPTION
  • GLYCOZYM PIPELINE PRODUCTS & ONGOING CLINICAL TRIALS OVERVIEW

It also offers antibody cancer drugs and IMABS for monoclonal antibodies.

  • Clinical Trial
  • Medical Biotechnology
  • Ovarian Cancer
  • United States
  • Pfizer Inc.

Seattle Genetics Inc (Seattle Genetics) is a biotechnology company that develops and commercializes monoclonal antibody-based therapies for the treatment of cancer.

  • Medical Biotechnology
  • Ovarian Cancer
  • United States
  • Company
  • Pharma Mar, S.A.
  • PIPELINE BY NEWLINK GENETICS CORP, H2 2018

It technologies include protein therapeutics, monoclonal antibodies and small molecular drugs.

  • Ovarian Cancer
  • Therapy
  • United States
  • Product Initiative
  • Cerulean
  • CLINICAL TRIAL PROFILE SNAPSHOTS

Hoffmann-La Roche Ltd ## ## ## ## ## Celgene Corp ## ## ## ## ## CTI BioPharma Corp ## ## ## ## ## Simcere Pharmaceutical Group ## ## ## ## ## GlaxoSmithKline Plc ## ## ## ## ## Bristol-Myers Squibb Co ## ## ## ## ## AbbVie Inc ## ## ## ##

  • Chemotherapy
  • Ovarian Cancer
  • Therapy
  • World
  • Product Initiative

Only one bispecific antibody is approved, and ## are in clinical development.

  • Breast Cancer
  • Epidemiology
  • Ovarian Cancer
  • Therapy
  • Product Initiative